BioVersys AG (SWX:BIOV)

Accolade Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	26.62	24.38
Short-Term Investments	6	4
Cash & Short-Term Investments	32.62	28.38
Cash Growth	14.95%	-
Other Receivables	1.29	2.07
Receivables	1.29	2.07
Prepaid Expenses	0.49	0.3
Other Current Assets	-	2.85
Total Current Assets	34.4	33.59
Property, Plant & Equipment	0.56	0.58
Total Assets	34.96	34.17
Accounts Payable	0.71	1.29
Accrued Expenses	3.45	2.2
Current Portion of Long-Term Debt	2.98	0.03
Current Portion of Leases	0.22	0.22
Current Unearned Revenue	1.15	1.07
Other Current Liabilities	1.17	4.55
Total Current Liabilities	9.67	9.37
Long-Term Debt	13.63	15.55
Long-Term Leases	0.13	0.13
Total Liabilities	24.27	25.59
Common Stock	3.69	3.06
Additional Paid-In Capital	87.4	68.77
Retained Earnings	-80.34	-62.94
Comprehensive Income & Other	-0.07	-0.32
Shareholders' Equity	10.68	8.58
Total Liabilities & Equity	34.96	34.17
Total Debt	16.97	15.93
Net Cash (Debt)	15.65	12.45
Net Cash Growth	25.77%	-
Net Cash Per Share	4.70	4.17
Filing Date Shares Outstanding	5.82	2.99
Total Common Shares Outstanding	0.33	2.99
Working Capital	24.73	24.22
Book Value Per Share	32.50	2.87
Tangible Book Value	10.68	8.58
Tangible Book Value Per Share	32.50	2.87
Machinery	0.58	0.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.